2. Academic Validation
  3. Quinoline-5,8-dione CDC25 inhibitors: Potent anti-cancer agents in leukemia and patient-derived colorectal organoids

Quinoline-5,8-dione CDC25 inhibitors: Potent anti-cancer agents in leukemia and patient-derived colorectal organoids

  • Eur J Med Chem. 2026 Jan 5:301:118215. doi: 10.1016/j.ejmech.2025.118215.
Iin Narwanti 1,  Zih-Yao Yu 2,  Bidyadhar Sethy 3,  Pei-Ling Zheng 2,  Li-Hsin Cheng 4,  Kelvin K Tsai 4,  Sung-Bau Lee 5,  Jing-Ping Liou 6
Affiliations

Affiliations

  • 1 School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; Faculty of Pharmacy, Universitas Ahmad Dahlan, Yogyakarta, Indonesia.
  • 2 Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • 3 School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan.
  • 4 Laboratory of Advanced Molecular Therapeutics, Graduate Institute of Clinical Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan; Core Laboratory of Organoids Technology, Office of R&D, Taipei Medical University, Taipei, Taiwan.
  • 5 Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; TMU Research Center of Drug Discovery, Taipei Medical University, Taipei, Taiwan. Electronic address: sbl@tmu.edu.tw.
  • 6 School of Pharmacy, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; Ph.D. Program in Drug Discovery and Development Industry, College of Pharmacy, Taipei Medical University, Taipei, Taiwan; TMU Research Center of Drug Discovery, Taipei Medical University, Taipei, Taiwan. Electronic address: jpl@tmu.edu.tw.
PMID: 41045697 DOI: 10.1016/j.ejmech.2025.118215
Abstract

Cell division cycle 25 (CDC25) phosphatases are critical activators of cyclin-dependent kinases (CDKs) and guardians of genome integrity, making them attractive Anticancer targets. Building on the quinoline-5,8-dione scaffold NSC663284 (6a), we synthesized derivatives with diverse C-6/C-7 alkylamino side chains. Structure-activity studies identified D3a/D3b (2-(4-methylpiperidin-1-yl)ethylamino) and D11a/D11b (2-(dimethylamino)ethylamino) as the most potent, exhibiting low-submicromolar inhibition of CDC25. In cell-based assays, these compounds suppressed leukemia (IC50 0.21-1.22 μM) and colorectal Cancer (IC50 0.13-1.50 μM) viability, with reduced toxicity in normal colonic epithelial cells. Mechanistically, these derivatives blocked CDC25-mediated CDK1 Tyr15 dephosphorylation, delayed G2/M progression, and induced caspase-dependent Apoptosis with DNA damage. Cytotoxic potency correlated with baseline CDC25C expression, confirming on-target activity. Notably, efficacy was validated in colorectal Cancer patient-derived organoids, providing clinically relevant insights into patient-specific responses. Together, these findings define a new class of CDC25 inhibitors with potent and selective Anticancer activity, advancing prospects for next-generation therapeutics in leukemia and colorectal Cancer.

Keywords

CDC25 inhibitors; Cancer therapeutics; Cell cycle arrest; Genomic instability; Patient-derived organoids; Quinoline-5,8-dione.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z